Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by jopatcloon Oct 14, 2024 3:57pm
75 Views
Post# 36265507

GranhamF the Vultur Back to 0.1099 (15 cents) on the US side

GranhamF the Vultur Back to 0.1099 (15 cents) on the US side
Remember  Hugh MacNaught “As more hospitals look to Ventripoint to provide advanced whole-heart analysis, this MDR submission is an important next step in the development and commercialization of the VMS+ family of devices” said Ventripoint President and CEO, Hugh MacNaught. “Upon approval we will be able to provide European cardiologists and care providers with one of the simplest, most-advanced, non-invasive heart-imaging tools available.” and on post Dr.Adams 
4. The Company has a license to sell VMS+4.0 in Canada and now it has submitted all the information needed for approval for Europe.  Our previous submissions for VMS+1.0, 2.0 and 3.0 were approved fairly quickly in about 6-8 weeks and so if this holds for this submission, we should have approval November.  We will see.
5. We continue to support the basic VMS+3.0 and upgrade users to the advanced VMS+3.2, while we wait for approvals for the premium VMS+4.0.
6. We recently upgraded Seattle Children’s Hopsital to VMS+3.2 and you can watch Dr, Soriano speak about his experiences on a new video on our website (https://youtu.be/Ucu6uGRMtEs+) from the Take Heart conference.
<< Previous
Bullboard Posts
Next >>